镥-PSMA-617放射性配体疗法用于转移性去势抵抗性前列腺癌：准备好进行III期试验了吗？ - Suppr

Suppr

超能文献

Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

作者信息

Rahbar Kambiz, Ahmadzadehfar Hojjat, Boegemann Martin

机构信息

Department of Nuclear Medicine, University Hospital Muenster, 48149, Münster, Germany.

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

出版信息

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):513-514. doi: 10.1007/s00259-017-3892-0. Epub 2017 Nov 21.

DOI:10.1007/s00259-017-3892-0

PMID:29164300

Abstract

摘要

相似文献

Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):513-514. doi: 10.1007/s00259-017-3892-0. Epub 2017 Nov 21.

Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670. doi: 10.1007/s00259-017-3751-z. Epub 2017 Jun 17.

Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.

Clin Nucl Med. 2018 Oct;43(10):728-734. doi: 10.1097/RLU.0000000000002210.

Clinical Outcomes of Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy.

J Nucl Med. 2019 Jul;60(7):955-962. doi: 10.2967/jnumed.118.216820. Epub 2019 Jan 25.

Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):166-167. doi: 10.1007/s00259-016-3530-2. Epub 2016 Oct 4.

Exceptional 4-year response to Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2212-2213. doi: 10.1007/s00259-019-04410-8. Epub 2019 Jul 4.

Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.

Clin Nucl Med. 2018 Oct;43(10):755-756. doi: 10.1097/RLU.0000000000002212.

[PSMA radioligand therapy in patients with advanced prostate cancer].

Urologe A. 2020 Jun;59(6):680-686. doi: 10.1007/s00120-020-01205-w.

225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.

Clin Nucl Med. 2020 Jun;45(6):437-438. doi: 10.1097/RLU.0000000000003031.

Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.

引用本文的文献

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.

BMC Urol. 2022 Jul 4;22(1):96. doi: 10.1186/s12894-022-01050-3.

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology.

Pharmaceuticals (Basel). 2020 Jan 30;13(2):22. doi: 10.3390/ph13020022.

From the respective expert viewpoints of the ANM specialty editors.

Ann Nucl Med. 2019 Dec;33(12):877-880. doi: 10.1007/s12149-019-01421-1. Epub 2019 Nov 19.

Efficacy and safety of Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia - A prospective study.

World J Nucl Med. 2019 Jul-Sep;18(3):258-265. doi: 10.4103/wjnm.WJNM_66_18.

Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics.

J Nucl Med. 2019 Nov;60(11):1504-1506. doi: 10.2967/jnumed.119.234054. Epub 2019 Aug 26.

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018.

本文引用的文献

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19. doi: 10.1007/s00259-017-3848-4. Epub 2017 Oct 12.

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

J Clin Oncol. 2016 Sep 1;34(25):3005-13. doi: 10.1200/JCO.2015.65.5597. Epub 2016 Jul 11.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验